254 related articles for article (PubMed ID: 28131876)
21. The Second-Generation PIM Kinase Inhibitor TP-3654 Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Cytotoxic Anticancer Drugs.
Wu CP; Li YQ; Chi YC; Huang YH; Hung TH; Wu YS
Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502348
[TBL] [Abstract][Full Text] [Related]
22. PCI29732, a Bruton's Tyrosine Kinase Inhibitor, Enhanced the Efficacy of Conventional Chemotherapeutic Agents in ABCG2-Overexpressing Cancer Cells.
Ge C; Wang F; Cui C; Su X; To KKW; Wang X; Zhang H; Song X; Fu L
Cell Physiol Biochem; 2018; 48(6):2302-2317. PubMed ID: 30114704
[TBL] [Abstract][Full Text] [Related]
23. Reversal of breast cancer resistance protein (BCRP/ABCG2)-mediated drug resistance by novobiocin, a coumermycin antibiotic.
Shiozawa K; Oka M; Soda H; Yoshikawa M; Ikegami Y; Tsurutani J; Nakatomi K; Nakamura Y; Doi S; Kitazaki T; Mizuta Y; Murase K; Yoshida H; Ross DD; Kohno S
Int J Cancer; 2004 Jan; 108(1):146-51. PubMed ID: 14618629
[TBL] [Abstract][Full Text] [Related]
24. Epidermal growth factor receptor (EGFR) inhibitor PD153035 reverses ABCG2-mediated multidrug resistance in non-small cell lung cancer: In vitro and in vivo.
Zhang GN; Zhang YK; Wang YJ; Gupta P; Ashby CR; Alqahtani S; Deng T; Bates SE; Kaddoumi A; Wurpel JND; Lei YX; Chen ZS
Cancer Lett; 2018 Jun; 424():19-29. PubMed ID: 29518481
[TBL] [Abstract][Full Text] [Related]
25. Vatalanib sensitizes ABCB1 and ABCG2-overexpressing multidrug resistant colon cancer cells to chemotherapy under hypoxia.
To KK; Poon DC; Wei Y; Wang F; Lin G; Fu LW
Biochem Pharmacol; 2015 Sep; 97(1):27-37. PubMed ID: 26206183
[TBL] [Abstract][Full Text] [Related]
26. Tandutinib (MLN518/CT53518) targeted to stem-like cells by inhibiting the function of ATP-binding cassette subfamily G member 2.
Zhao XQ; Dai CL; Ohnuma S; Liang YJ; Deng W; Chen JJ; Zeng MS; Ambudkar SV; Chen ZS; Fu LW
Eur J Pharm Sci; 2013 Jun; 49(3):441-50. PubMed ID: 23619284
[TBL] [Abstract][Full Text] [Related]
27. Cabozantinib reverses multidrug resistance of human hepatoma HepG2/adr cells by modulating the function of P-glycoprotein.
Xiang QF; Zhang DM; Wang JN; Zhang HW; Zheng ZY; Yu DC; Li YJ; Xu J; Chen YJ; Shang CZ
Liver Int; 2015 Mar; 35(3):1010-23. PubMed ID: 24621440
[TBL] [Abstract][Full Text] [Related]
28. SIS3, a specific inhibitor of Smad3 reverses ABCB1- and ABCG2-mediated multidrug resistance in cancer cell lines.
Wu CP; Murakami M; Hsiao SH; Liu TC; Yeh N; Li YQ; Hung TH; Wu YS; Ambudkar SV
Cancer Lett; 2018 Oct; 433():259-272. PubMed ID: 30026175
[TBL] [Abstract][Full Text] [Related]
29. Ulixertinib (BVD-523) antagonizes ABCB1- and ABCG2-mediated chemotherapeutic drug resistance.
Ji N; Yang Y; Lei ZN; Cai CY; Wang JQ; Gupta P; Xian X; Yang DH; Kong D; Chen ZS
Biochem Pharmacol; 2018 Dec; 158():274-285. PubMed ID: 30431011
[TBL] [Abstract][Full Text] [Related]
30. Effect of ceritinib (LDK378) on enhancement of chemotherapeutic agents in ABCB1 and ABCG2 overexpressing cells in vitro and in vivo.
Hu J; Zhang X; Wang F; Wang X; Yang K; Xu M; To KK; Li Q; Fu L
Oncotarget; 2015 Dec; 6(42):44643-59. PubMed ID: 26556876
[TBL] [Abstract][Full Text] [Related]
31. Bafetinib (INNO-406) reverses multidrug resistance by inhibiting the efflux function of ABCB1 and ABCG2 transporters.
Zhang YK; Zhang GN; Wang YJ; Patel BA; Talele TT; Yang DH; Chen ZS
Sci Rep; 2016 May; 6():25694. PubMed ID: 27157787
[TBL] [Abstract][Full Text] [Related]
32. WHI-P154 enhances the chemotherapeutic effect of anticancer agents in ABCG2-overexpressing cells.
Zhang H; Zhang YK; Wang YJ; Kathawala RJ; Patel A; Zhu H; Sodani K; Talele TT; Ambudkar SV; Chen ZS; Fu LW
Cancer Sci; 2014 Aug; 105(8):1071-8. PubMed ID: 24903205
[TBL] [Abstract][Full Text] [Related]
33. Y
Zhao RQ; Wen Y; Gupta P; Lei ZN; Cai CY; Liang G; Yang DH; Chen ZS; Xie YA
Front Pharmacol; 2018; 9():1545. PubMed ID: 30687102
[TBL] [Abstract][Full Text] [Related]
34. Telatinib reverses chemotherapeutic multidrug resistance mediated by ABCG2 efflux transporter in vitro and in vivo.
Sodani K; Patel A; Anreddy N; Singh S; Yang DH; Kathawala RJ; Kumar P; Talele TT; Chen ZS
Biochem Pharmacol; 2014 May; 89(1):52-61. PubMed ID: 24565910
[TBL] [Abstract][Full Text] [Related]
35. The epidermal growth factor tyrosine kinase inhibitor AG1478 and erlotinib reverse ABCG2-mediated drug resistance.
Shi Z; Parmar S; Peng XX; Shen T; Robey RW; Bates SE; Fu LW; Shao Y; Chen YM; Zang F; Chen ZS
Oncol Rep; 2009 Feb; 21(2):483-9. PubMed ID: 19148526
[TBL] [Abstract][Full Text] [Related]
36. Elacridar enhances the cytotoxic effects of sunitinib and prevents multidrug resistance in renal carcinoma cells.
Sato H; Siddig S; Uzu M; Suzuki S; Nomura Y; Kashiba T; Gushimiyagi K; Sekine Y; Uehara T; Arano Y; Yamaura K; Ueno K
Eur J Pharmacol; 2015 Jan; 746():258-66. PubMed ID: 25455500
[TBL] [Abstract][Full Text] [Related]
37. ABCG2-overexpressing H460/MX20 cell xenografts in athymic nude mice maintained original biochemical and cytological characteristics.
Zhang W; Chen Z; Chen L; Wang F; Li F; Wang X; Fu L
Sci Rep; 2017 Jan; 7():40064. PubMed ID: 28059154
[TBL] [Abstract][Full Text] [Related]
38. Effects of dihydropyridines and pyridines on multidrug resistance mediated by breast cancer resistance protein: in vitro and in vivo studies.
Zhou XF; Yang X; Wang Q; Coburn RA; Morris ME
Drug Metab Dispos; 2005 Aug; 33(8):1220-8. PubMed ID: 15908473
[TBL] [Abstract][Full Text] [Related]
39. Pelitinib (EKB-569) targets the up-regulation of ABCB1 and ABCG2 induced by hyperthermia to eradicate lung cancer.
To KK; Poon DC; Wei Y; Wang F; Lin G; Fu L
Br J Pharmacol; 2015 Aug; 172(16):4089-106. PubMed ID: 25988710
[TBL] [Abstract][Full Text] [Related]
40. Cyclosporin A, tacrolimus and sirolimus are potent inhibitors of the human breast cancer resistance protein (ABCG2) and reverse resistance to mitoxantrone and topotecan.
Gupta A; Dai Y; Vethanayagam RR; Hebert MF; Thummel KE; Unadkat JD; Ross DD; Mao Q
Cancer Chemother Pharmacol; 2006 Sep; 58(3):374-83. PubMed ID: 16404634
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]